Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Hutt

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Deutsche Medizinische Wochenschrift (1946)|February 14, 1992
[The prevention of nonsteroidal antirheumatic agent-associated gastropathy]H J Hutt, H Mielenz
Deutsche Medizinische Wochenschrift (1946)|April 9, 2009
[Vaccinations: strategies and comprehension]H J Hutt, W Kirch
Clinical Pharmacokinetics|October 1, 1988
The influence of renal function on clinical pharmacokinetics of moxonidineW Kirch, H J Hutt, V Plänitz
Fortschritte Der Medizin|October 30, 1990
[Gaviscon in reflux symptoms. Results of a drug monitoring study]H J Hutt, O Tauber, D Flach
Journal of Clinical Pharmacology|December 1, 1990
Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patientsW Kirch, H J Hutt, V Plänitz
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement|January 1, 1986
Dose-dependence of the nifedipine/digoxin interaction?H J Hutt, W Kirch, P Dylewicz, et al.
Arzneimittel-Forschung|November 1, 1996
[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]B Heintz, A Müller, G Lenhard, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1987
Ketanserin versus nifedipine in secondary Raynaud's phenomenonW Kirch, H R Linder, H J Hutt, et al.
Clinical Pharmacology and Therapeutics|January 1, 1986
Dose-dependence of the nifedipine-digoxin interaction?W Kirch, H J Hutt, P Dylewicz, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Bioavailability and elimination of nitrendipine in liver diseaseP Dylewicz, W Kirch, S R Santos, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|February 14, 1992
[The prevention of nonsteroidal antirheumatic agent-associated gastropathy]H J Hutt, H Mielenz
Deutsche Medizinische Wochenschrift (1946)|April 9, 2009
[Vaccinations: strategies and comprehension]H J Hutt, W Kirch
Clinical Pharmacokinetics|October 1, 1988
The influence of renal function on clinical pharmacokinetics of moxonidineW Kirch, H J Hutt, V Plänitz
Fortschritte Der Medizin|October 30, 1990
[Gaviscon in reflux symptoms. Results of a drug monitoring study]H J Hutt, O Tauber, D Flach
Journal of Clinical Pharmacology|December 1, 1990
Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patientsW Kirch, H J Hutt, V Plänitz
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement|January 1, 1986
Dose-dependence of the nifedipine/digoxin interaction?H J Hutt, W Kirch, P Dylewicz, et al.
Arzneimittel-Forschung|November 1, 1996
[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]B Heintz, A Müller, G Lenhard, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1987
Ketanserin versus nifedipine in secondary Raynaud's phenomenonW Kirch, H R Linder, H J Hutt, et al.
Clinical Pharmacology and Therapeutics|January 1, 1986
Dose-dependence of the nifedipine-digoxin interaction?W Kirch, H J Hutt, P Dylewicz, et al.
European Journal of Clinical Pharmacology|January 1, 1987
Bioavailability and elimination of nitrendipine in liver diseaseP Dylewicz, W Kirch, S R Santos, et al.
Pageof 2